UPCC 01622 Neoadjuvant PD-1 blockade in resectable Merkel cell carcinoma
Enrolling By Invitation
99 years and younger
All
Phase
1
15 participants needed
1 Location
Brief description of study
Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please reer to Protocol Section 3.2 (Secondary Objective(s), Hypothesis(es), and Endpoint(s)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 851460
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
